AzTrials
AzTrials

AnxietyNCT07805070

Uncovering Neurocognitive Mechanisms and Enhancement of Exposure-based Fear Learning With Cognitive Training

A study testing Cognitive training in people with Anxiety and Fear Extinction, run by University of California, San Diego.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record

Search all trials

Trial summary

Anxiety disorders remain are among the most prevalent psychiatric conditions and are associated with negative outcomes spanning poor health to increased suicide risk. While exposure therapy is recognized as a gold standard empirically supported treatment, many individuals fail to achieve adequate response. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anxiety, Fear Extinction
What is being tested?
Cognitive training
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
No sites listed yet
Study dates
1 Jan 2027to 1 Sep 2031
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age 18-65
  • fluent in English
  • diagnosis of social anxiety disorder (generalized or performance-only) with Personal Report of Public Speaking Anxiety (PRPSA) score of ≥120 at screening
  • 6-week stability if receiving other (non-anxiety focused) psychosocial treatment

Who cannot join

  • past 3-mo diagnosis of moderate or greater alcohol or substance use disorder
  • lifetime history of psychotic or bipolar I disorders
  • acute suicidality necessitating immediate clinical intervention
  • neurodegenerative or neurodevelopmental disorders
  • history of neurological condition
  • conditions that are unsafe for MRI (e.g., metal in body)
  • currently receiving psychosocial treatment for anxiety or related condition
  • currently receiving psychiatric pharmacotherapy

About this study

Anxiety disorders remain are among the most prevalent psychiatric conditions and are associated with negative outcomes spanning poor health to increased suicide risk. While exposure therapy is recognized as a gold standard empirically supported treatment, many individuals fail to achieve adequate response. Exposure therapy is grounded in fear extinction learning models, which suggest that anxiety diminishes when individuals repeatedly confront their fears. To improve exposure-based interventions, it is critical to enhance our understanding of underlying mechanisms of fear extinction and how to better target these mechanisms. Fear extinction requires basic neurocognitive abilities that allow individuals to learn from and adapt to experiences confronting feared situations. Emerging cross sectional and experimental data suggest that working memory is a particularly important neurocognitive process that is associated with fear learning outcomes. By enhancing working memory through experimental manipulations like cognitive training, we may improve the fear extinction learning processes essential for successful exposure therapy. Unlike other neurocognitive enhancements (e.g., medications), computer-based working memory training offers high mechanistic precision, ease of administration, and low cost. The long-term goal of this research is to develop a novel mechanistic understanding of the neurocognitive processes involved in exposure-based fear extinction learning, ultimately aiming to improve interventions for anxiety disorders. This study will test the effects of manipulating working memory prior to a massed exposure paradigm, comparing working memory training plus massed exposure (WMT+Ex) to a sham training plus massed exposure (ST+Ex) condition. Using public speaking anxiety as a clinical exemplar, we will employ a rigorous experimental trial design combined with a validated single-visit speech exposure paradigm to assess fear extinction learning outcomes through multiple measures, including behavioral, physiological, neural, and self-report. The central hypothesis is that WMT+Ex will improve markers of fear extinction learning considered to underlie clinical response in exposure therapy. Specific aims are to 1) determine the extent to which working memory training delivered prior to massed exposure improves behavioral and neural markers of fear extinction learning, and 2) evaluate the effects of working memory training delivered prior to massed exposure on fear extinction learning occurring during exposure. This study is expected to achieve two goals: first, to advance our understanding of the neurocognitive mechanisms of fear extinction through a rigorous experimental design, and second, to validate a combined working memory training and exposure paradigm. If successful in enhancing fear extinction, this approach could be further explored in therapeutic formats to assess its clinical effects.

Being tested
Cognitive training
Keywords
anxiety, social phobia
Medical subject headings
Anxiety Disorders, Phobia, Social

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive trainingBehavioural

    Repeated practice with cognitive skills to enhance performance

  • Cognitive trainingBehavioural

    Sham cognitive training

Study groups in NCT07805070
Study groupRoleWhat they receive
Cognitive trainingActive comparatorTraining to enhance cognitive functioning
Receives: Behavioral: Cognitive training
Sham trainingSham comparatorComputer interface designed to control for general task parameters
Receives: Behavioral: Cognitive training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fear extinction

    threat expectancy ratings to the CS+ during late extinction learning

    Measured: Change from baseline day 1 to post-intervention day 2

  2. Subjective Units of Distress

    Ratings of distress during speeches

    Measured: Change from baseline speech to post speech (all within day 1)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2026
  2. Study start1 Jan 2027 (estimated)
  3. Primary completion1 Jun 2031 (estimated)
  4. Study completion1 Sep 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07805070
Sponsor's protocol ID
812820
Other IDs
1R01MH141088-01A1
Status last verified
Sep 2026
First submitted
31 Aug 2026
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: NIH NDA

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in